
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Company's internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe fo... Geron is a commercial-stage biopharmaceutical company focused on research, development, and commercialization of the Company's internally developed first-in-class telomerase inhibitor for the treatment of hematologic malignancies. RYTELO(R) (imetelstat) is approved in the United States and Europe for treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with a telomerase inhibitor approved by the FDA and the EC, Geron is exploring the broad potential of imetelstat across multiple myeloid hematologic malignancies. In addition to its Phase 3 trial for JAK inhibitor relapsed/refractory myelofibrosis (R/R MF), Geron has programs assessing imetelstat in additional indications, as a single agent and in combination with current standard of care therapies through early-stage clinical trials.The company earns revenue through RYTELO sales and possesses global rights to imetelstat. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -4.4776119403 | 1.34 | 1.39 | 1.17 | 12037223 | 1.29578836 | CS |
4 | -0.42 | -24.7058823529 | 1.7 | 1.89 | 1.17 | 15216984 | 1.52160463 | CS |
12 | -1.74 | -57.6158940397 | 3.02 | 3.12 | 1.17 | 15788728 | 1.9525292 | CS |
26 | -2.88 | -69.2307692308 | 4.16 | 4.5 | 1.17 | 12820428 | 2.69744773 | CS |
52 | -2.35 | -64.738292011 | 3.63 | 5.34 | 1.17 | 11409722 | 3.44437682 | CS |
156 | -0.27 | -17.4193548387 | 1.55 | 5.34 | 1.17 | 7884924 | 2.96286668 | CS |
260 | 0.08 | 6.66666666667 | 1.2 | 5.34 | 0.9899 | 6090535 | 2.66956658 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions